Transgene Reports First Patient Dosed in Phase 1 BT-001 Trial for Rectal Cancer

Bitget2026/11/05 07:02

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Transgene announced today that the first patient received treatment in the Phase 1 OV-PRIME-R trial for localized rectal cancer.
The University of Copenhagen-sponsored study tests BT-001, co-developed with BioInvent, followed by pembrolizumab in patients with proficient mismatch repair status.
The trial evaluates safety, tolerability and efficacy before standard surgery, aiming to reduce relapse risk and potentially avoid surgery.
Previously reported clinical findings showed BT-001 was well tolerated and stimulated antitumor immune responses in patients with treatment-resistant metastatic cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050200OMX_____CNEWS_EN_GNW1001301885_en) on November 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Transgene Reports First Patient Dosed in Phase 1 BT-001 Trial for Rectal Cancer

You may also like

Crypto prices